- Home
- BMRN vs FAASW Comparison
BMRN vs FAASW Comparison
Compare BMRN & FAASW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- FAASW
- Stock Information
- Founded
- BMRN 1996
- FAASW N/A
- Country
- BMRN United States
- FAASW United States
- Employees
- BMRN N/A
- FAASW N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- FAASW
- Sector
- BMRN Health Care
- FAASW
- Exchange
- BMRN Nasdaq
- FAASW Nasdaq
- Market Cap
- BMRN 13.7B
- FAASW N/A
- IPO Year
- BMRN 1999
- FAASW 2021
- Fundamental
- Price
- BMRN $70.52
- FAASW $0.06
- Analyst Decision
- BMRN Buy
- FAASW
- Analyst Count
- BMRN 22
- FAASW 0
- Target Price
- BMRN $94.00
- FAASW N/A
- AVG Volume (30 Days)
- BMRN 1.6M
- FAASW N/A
- Earning Date
- BMRN 04-23-2025
- FAASW N/A
- Dividend Yield
- BMRN N/A
- FAASW N/A
- EPS Growth
- BMRN 153.71
- FAASW N/A
- EPS
- BMRN 2.21
- FAASW N/A
- Revenue
- BMRN $2,853,915,000.00
- FAASW N/A
- Revenue This Year
- BMRN $12.23
- FAASW N/A
- Revenue Next Year
- BMRN $9.90
- FAASW N/A
- P/E Ratio
- BMRN $31.97
- FAASW N/A
- Revenue Growth
- BMRN 17.97
- FAASW N/A
- 52 Week Low
- BMRN $60.63
- FAASW N/A
- 52 Week High
- BMRN $94.85
- FAASW N/A
- Technical
- Relative Strength Index (RSI)
- BMRN 59.12
- FAASW N/A
- Support Level
- BMRN $69.89
- FAASW N/A
- Resistance Level
- BMRN $73.51
- FAASW N/A
- Average True Range (ATR)
- BMRN 2.04
- FAASW 0.00
- MACD
- BMRN 0.16
- FAASW 0.00
- Stochastic Oscillator
- BMRN 52.81
- FAASW 0.00
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
About FAASW DigiAsia Corp. Warrant
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.